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Background: Duchenne muscular dystrophy is a genetic disease involving a severe muscle wasting that is
characterized by cycles of muscle degeneration/regeneration and culminates in early death in affected boys.
Mitochondria are presumed to be involved in the regulation of myoblast proliferation/differentiation; enhancing
mitochondrial activity with exercise mimetics (AMPK and PPAR-delta agonists) increases muscle function and
inhibits muscle wasting in healthy mice. We therefore asked whether metabolic remodeling agents that increase
mitochondrial activity would improve muscle function in mdx mice.
Methods: Twelve-week-old mdx mice were treated with two different metabolic remodeling agents (GW501516
and AICAR), separately or in combination, for 4 weeks. Extensive systematic behavioral, functional, histological,
biochemical, and molecular tests were conducted to assess the drug(s)' effects.
Results: We found a gain in body and muscle weight in all treated mice. Histologic examination showed a
decrease in muscle inflammation and in the number of fibers with central nuclei and an increase in fibers with
peripheral nuclei, with significantly fewer activated satellite cells and regenerating fibers. Together with an
inhibition of FoXO1 signaling, these results indicated that the treatments reduced ongoing muscle damage.
Conclusions: The three treatments produced significant improvements in disease phenotype, including an increase
in overall behavioral activity and significant gains in forelimb and hind limb strength. Our findings suggest that
triggering mitochondrial activity with exercise mimetics improves muscle function in dystrophin-deficient mdx
mice.
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Muscle is a plastic tissue that responds and adapts to en-
vironmental changes [1]. Energy balance is one of the
checkpoints between muscle growth/hypertrophy and
protein breakdown [2], and >10% of atrophy-related
genes are directly involved in energy production [3-5].
Mitochondrial dysfunction activates various proteolytic
systems [2] and is associated with muscle atrophy in sev-
eral myopathies [6,7]. Peroxisome proliferator-activated* Correspondence: knagaraju@cnmcresearch.org
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reproduction in any medium, provided the orreceptor γ coactivator 1 α (PGC-1α), the master regula-
tor of mitochondrial biogenesis [8], seems to control
muscle wasting [3]. PGC-1α overexpression increases
mitochondrial content [9] and resistance to fatigue [9]
and reduces the rapid muscle atrophy associated with
denervation, fasting, and FoXO 3 activation [3]. Re-
cently, mice overexpressing PGC-1α have been shown to
have an increased lifespan and to be protected from sar-
copenia [10]. Therefore, targeting mitochondrial biogen-
esis and metabolism up-regulation may have beneficial
effects in muscle diseases.
Evidence for the beneficial effects of submaximal aer-
obic activities in DMD patients is slowly emerging. A re-
cent review on the management and care of DMDLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ambulatory-stage boys participate in regular submaximal
functional activities [11]. The molecular mechanisms by
which exercise provides beneficial effects are currently
unclear. However, increased PPARδ and AMPK activities
have been implicated in these beneficial effects [12]. We
hypothesized that exercise mimetics activating PPARδ
and AMPK pathways are beneficial to dystrophin defi-
cient skeletal muscle. In the present study, we have used
agonists of PPARδ (GW501516) and AMPK (AICAR) to
activate beneficial endurance exercise-induced signaling
pathways in mdx mice. We have demonstrated that en-
durance mimetics can improve muscle function by halt-




All mice were handled according to Washington DC
Veterans Affairs Medical Center’s Institutional Animal
Care and Use Committee guidelines under approved
protocol # 01079. C57BL/10ScSn-Dmdmdx/J (mdx)
8-week-old male mice, 20-30g, were purchased from
The Jackson Laboratory housed in an individually vented
cage system (with a 12-h light–dark cycle, standard
mouse chow and water ad libitum). Mice were rested
for 10–14 days, acclimatized on the behavioral instru-
ment for 1 week and then baseline grip strength and be-
havioral activity was performed. At 12 weeks of age, the
mice were given AICAR (250mg/kg [80μl]; Alexis) by
intraperitoneal injection and/or GW501516 (7.5mg/kg
[80μl]; Alexis) by oral gavage, 5 days/week for 4 weeks.
DMSO in PBS (1/2 vol/vol) was used as a vehicle control
and concentration of DMSO was the same in vehicle
and drug treatments.
Extensor digitorum longus (EDL) fiber isolation and
staining
The EDL muscles of 12-week-old mice were harvested
and incubated in DMEM with 2mg/ml collagenase for
2 h. EDL fibers were separated with Pasteur pipets. Fibers
were rinsed, stained with 10-nonyl acridine orange (NAO;
Sigma) (15min), rinsed, fixed with 4% formalin (10min),
and mounted. Pictures were taken. Fluorescence levels
were analyzed with ImageJ software (NIH).
LDH activity
Lactate dehydrogenase activity of muscle lysate was mea-
sured using 2.5μl of protein extract (1:2 dilution), 225μl
assay buffer (2.5ml of 1 M Tris [pH 7.6], 500μl of
200mM EDTA, and 500μl of 5mM NADH,H+, and 48ml
water). Oxidation of NADH, H+ was recorded after pyru-
vate addition (10μl, 100mM). NADH fluorescence was
detected by luminescence/fluorescence analyzer (MithrasLB 940, Berthold Technologies). LDH activity was nor-
malized to protein concentration.Measurement of contraction properties
Mice were anesthetized with 100mg/kg ketamine and
10mg/kg xylazine. EDL muscle was isolated and placed
in Ringer’s solution (137mM NaCl, 24mM NaHCO3,
11mM glucose, 5mM KCl, 2mM CaCl2, 1mM MgSO4,
1mM NaH2PO4, and 0.025mM tubocurarine chloride)
maintained at 25°C and bubbled with 95% O2-5% CO2.
Contractile properties were measured according to
Brooks et al. [13], using an in vitro test apparatus (model
305B, Aurora Scientific). A fatigue protocol was per-
formed (20 min, 100 Hz). EDL muscle was subjected to a
series of 120 isometric tetanic contractions (400 ms).Behavioral activity measurement and grip strength
testing
All animals were weighed before and after drug treatment.
Grip strength and open-field activity were assessed using a
grip strength meter (Columbus Instruments, Columbus,
OH) and open-field Digiscan apparatus (Omnitech Elec-
tronics, Columbus, Ohio), respectively, as described previ-
ously [14]. Tissues were either embedded in OCT or
wrapped in foil and then frozen in isopentane chilled in li-
quid nitrogen. Blood was collected by cardiac puncture,
and serum was collected by centrifuging blood for 10min
at 10,000rpm and then stored at −80°C.Muscle cell extraction
Leg muscles that were not harvested as previously
described were used for satellite cell extraction. Tendons
and aponeuroses were removed. Muscles were minced,
placed in digestion medium (2.4U/ml dispase II, 100mg/
ml collagenase A), vortexed, and incubated at 37°C. After
digestion, tubes were placed on ice, and 25ml of DMEM-
1% PS-2% L-Glut were added. The mixture was filtered
with a 100-μm cell strainer and centrifuged (800g, 4°C,
3min). The pellet was resuspended in 25ml DMEM-1%
PS-2% L-Glut), filtered with a 70-μm cell strainer, and
centrifuged (800g, 4°C, 3min). The same operation was
repeated with a 40-μm cell strainer. Cell extracts were fro-
zen and stored at −80°C.Flow cytometry analyses
Mitochondrial content and inner membrane potential (ΔΨ)
were assessed with NAO and 3, 3’-dihexyloxacarbocyanine
iodide (DiOC6) (Invitrogen) as described [15]. Cell immu-
noreactivity against MyoD (Dako) was assessed with
Hoechst 33342 (Sigma) as described [15]. Cells were ana-
lyzed on a FACSCalibur (BD Biosciences, San Jose, CA,
USA) with BD Cell Quest ProTM 4.0.2.
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Total DNA was extracted from muscle cells using DNeasy
blood and tissue kit (Qiagen). The content of mtDNA was
calculated using real-time quantitative PCR by measuring
the threshold cycle ratio (ΔCt) of a mitochondrial-
encoded gene (ND1, forward 5’- GGA CCT AAG CCC
AAT AAC GA-3’, reverse 5’-GCT TCA TTG GCT ACA
CCT TG-3’) versus a nuclear-encoded gene (Beta-globu-
lin, forward 5’-CTT CTG GCT ATG TTT CCC TT-3’,
reverse 5’-GTT CTC AGG ATC CAC ATG CA-3’).
NADH activity
Frozen sections were incubated in working solution (8mg/
5ml NADH and 10mg/5ml NBT, 30 min, 37°C) Sections
were rinsed thrice in water, with three exchanges each in
30, 60, and 90% acetone solution, then incubated in 90%
acetone until a faint purplish cloud was seen over each
section. Sections were then rinsed several times with water
and mounted. All sections were stained at the same time
to avoid experimental variation. Pictures were analyzed
using ImageJ.
Immunohistochemistry and cytokine analysis
Isolated muscle cells and frozen sections were fixed in
ethanol (except for developmental myosin heavy chain
[dMHC] staining), rinsed, and incubated (30 min, 20°C)
with blocking solution (PBS, 2% BSA, 0.5% Triton
X-100, 0.1% Tween 20, 20% sheep serum). Samples were
washed and incubated with dMHC (DSHB), MyoD
(Dako), or IgM overnight at 4°C, then washed and incu-
bated for 60 min (20°C) with the appropriate secondary
antibody and Hoechst 33342 (9.0μM, 10 min) and ana-
lyzed as described above.
Cytokine expression in EDL muscle lysate was
assessed by flow cytometry with a Mouse Inflammation
Kit (BD Biosciences 552364), as described in the manu-
facturer’s instructions.
Hematoxylin and eosin (H&E) staining and fibrosis
measurement
EDL muscle sections were stained with H&E. The fol-
lowing parameters were assessed: the number of total
fibers present, total fibers with central nuclei, total per-
ipheral nuclei (dark-blue nuclei), total central nuclei, re-
generating fibers (purple), degenerating fibers (pale
pink), and inflammation (an interstitial group of 10
smaller inflammatory cells with dark-blue nuclei in a
field) in five non-overlapping fields in each EDL muscle
section. Fibers intersecting the left and top borders of
the field were not counted, and nuclei farther than one
nuclear diameter from the fiber border were considered
central nuclei. Frozen sections were stained with Van
Gieson stain (Sigma-Aldrich, St. Louis, MO). Sections
were imaged (bright field, 4× objective, Olympus C.A.S.T. Stereology System, Olympus America Inc., Center
Valley, PA). Pictures were processed using ImageJ. Fi-
brotic red areas were expressed as a percentage of the
total tissue section.
Western blotting
Protein homogenates were extracted as previously
described [16]. Proteins were separated on 4-12% Nupage
Bis/Tris gels. After electro transfer, membranes were satu-
rated with 5% non-fat dry milk (1h, 20°C) and incubated
overnight with primary antibody against FoXO1 (1/1,000)
(cell signaling), utrophin A (1/1,000) (DSHB), or vinculin
(1/10,000) (Sigma), then with the corresponding secondary
antibodies (1/5,000) (Dako) for 90 min. Immunoreactivity
was determined by chemiluminescence and quantified with
Quantity One (Bio-Rad).
RNA extraction and MiRNA gene expression
RNA was extracted using an miRNeasy Mini Kit (Qiagen,
Valencia, CA). Reverse transcription (RT) was performed
with a TaqMan microRNA reverse transcription kit (Life
Technologies Co., Applied Byosystems, Carlsbad, CA).
miRNA expression was calculated using real-time quanti-
tative PCR by measuring the threshold cycle ratio (ΔCt)
of miRNA31 (3’-AGGCAAGAUGCUGGCAUAGCUG-5’)
and miRNA133a (3’-UUUGGUCCCCUUCAACCAGCU
G-5’) versus endogenous control snoRNA202 (3’-GCUG
UACUGACUUGAUGAAAGUACUUUUGA-5’). mRNA
expression was calculated using real-time quantitative
PCR by measuring the threshold cycle ratio (ΔCt) of PGC-
1α mRNA (5′ CCT GGC CGA GTT CTT TGA A 3′, 5′
GCC AGA TTT GCT TGT TTG G 3′), cyt c mRNA (5'
TGC CCA GTG CCA CAC TGT 3', 5' CTG TCT TCC
GCC CGA ACA 3'), PDK-4 mRNA (5′ CCG CTG TCC
ATG AAG CA 3′, 5′ GCA GAA AAG CAA AGG ACG
TT 3′) versus endogenous control GAPDH mRNA (5’
CCG TTC AGC TCT GGG ATG AC 3’, 5’ TTC TCA
GCA ATG CAT CCT GC 3’).
Statistical analyses
The mean difference between treated and untreated
mice was determined by one-way analysis of variance.
Scheffé’s post hoc test was used to identify specific mean
differences.
Results
Effect of dystrophin deficiency on mitochondrial
metabolism
Evaluation of mitochondrial mass (NAO staining) in EDL
fibers of mdx mice and WT control mice (Figure 1A)
showed that dystrophin-deficient muscle fibers have
decreased mitochondrial mass, indicating that these
muscle have a lower capacity to use oxidative energy.
Furthermore, assessment of LDH activity (Figure 1B)
Figure 1 Effect of dystrophin deficiency on mitochondrial mass and activity. (A) Isolated EDL fibers were stained with NAO dye to assess
mitochondrial mass (n = 3 animals and 30 fibers per muscles). Pictures of the dye fluorescence were taken at the same setting. Fluorescence was
quantified with ImageJ. (B) LDH enzyme activity was measured in TA muscle extracts (n = 6). (C) Isometric tetanic maximal force on EDL muscle
from mdx and WT mice (n = 6). (D) Fatigue force measurements of EDL muscles from WT and mdx mice (n = 6). Data are means ± SE.
* P < 0.05 vs. WT mice. *** P < 0.001 vs. WT mice.
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to produce lactate. These muscles also showed lower spe-
cific force than those of WT mice (Figure 1C), and fa-
tigue testing showed that dystrophin-deficient muscle
was more fatigable than that of WT mice (Figure 1D),
suggesting that dystrophin deficiency leads to significant
alterations in mitochondrial function and muscle metab-
olism. Comparison of the ratio of mtDNA to nDNA in
the gastrocnemius muscle of vehicle treated and drug
treated groups also suggested a trend in an increase of
the mtDNA in the AICAR and combination groups (data
not shown).
Effect of GW and AICAR on muscle weight and behavioral
activity measures
The average body mass of the treated mice was signifi-
cantly higher than that of vehicle-treated mice (Figure 2A).
Treatments increased the body mass by ~10% (GW, 9.2%;
AICAR, 11.3%; GW&AICAR, 10.63%). A general in-
crease in the weight of the EDL, gastrocnemius, quadri-
ceps, soleus, and TA muscles was found in the drug-treated groups (statistically significant for the quadriceps
(GW, +12.7%; AICAR, +14.6% ; GW&AICAR, 13.7%)
(Figure 2B) and soleus (GW, +14.3%; AICAR, +17.4%)
(Figure 2C). Interestingly, abdominal fat was decreased
in response to all three treatments (Figure 2D), and the
decrease was statistically significant for both single-
treatment groups.
Grip strength and open-field animal activity tests were
performed before and after drug treatment. We found a
significant increase in forelimb grip strength in the
GW501516-treated and combination-treatment groups
(Figure 2E,F). The increase in hind limb grip strength
was significant for all three treatments (Figure 2G).
Since these drugs influenced body weight, we normal-
ized data to body weight. Both forelimb and hind limb
grip strength increased significantly with GW501516
(+19%, +13%, respectively) and combination treatment
(+25%, +13%, respectively) (Figure 2F). Behavioral activ-
ity measures did not significantly change for the single
treatments but the combination treatment group showed
significantly increased movement time (89%) (Figure 2I)
Figure 2 Effect of GW and AICAR on body mass, muscle mass, and behavioral activity. (A-D) Mass of vehicle control- (n = 8), GW- (n = 6),
AICAR- (n = 8), and GW&AICAR-treated (n = 6) mice: mass of the whole body (A), quadriceps (B), soleus (C), and abdominal fat (D) after
euthanasia. Grip strength was measured using a grid at 12 and 16 weeks of age: (E) Maximal forelimb grip strength, (F) normalized maximal
forelimb strength, (G) maximal hind-limb grip strength, (H) normalized maximal hind-limb strength of all the groups. The overall activity of the
mice was measured using the open-field Digiscan apparatus at 12 and 16 weeks of age: (I) movement time and (J) rest time activity. Behavioral
activity is presented as a percentage of the initial activity measured at 12 weeks of age before treatment. Data are means ± SE. * P < 0.05
vs. vehicle-treated control mice. **P < 0.01 vs. vehicle-treated control mice. *** P < 0.001 vs. vehicle-treated control mice.
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beneficial effect on these parameters.
Effect of GW and AICAR on mitochondrial activity
We evaluated the impact of these drugs on mitochondrial
activity in muscle cells isolated from hind limb muscles of
dystrophin-deficient mdx mice. A significant increase in
mitochondrial mass, as indicated by NAO staining, was
found in the GW501516-treated cells (Figure 3A,B). We
saw no significant increase in either the AICAR- or
combination-treated groups. Mitochondrial ΔΨ, as assessed
by DiOC6 staining, was significantly increased in response
to AICAR treatment (Figure 3C,D) but not GW501516
or combination treatment. Gastrocnemius muscle from
treated mdx mice expressed significantly more PGC-1 α,
cyt c mRNAs (Figure 3E,F) in comparison to vehicle
treated group but increase in PDK4 mRNA did not
reach statistical significance (Figure 3G). We also found
that NADH activity was significantly increased in EDL(Figure 3H) (GW, +43%; AICAR, +29%; GW&AICAR,
26%) and SOL (Figure 3I) muscle (GW, +35%; AICAR,
+26%; GW&AICAR, 13.7%) in response to drug treat-
ment. Soleus muscles expressed more myosin heavy
chain type I (Figure 3J), whereas only GW showed a sta-
tistically significant increase in type IIA fibers
(Figure 3K). This increase in oxidative capacity was also
observed in EDL muscles, in which the ratio of the
height of the twitch force (Pt) to the time to reach this
maximal force (tpt) was increased in single-treated mice
(GW, +18%; AICAR, +24% ) (Figure 3L). Finally, LDH
activity in the TA was decreased in all three treatment
groups, but the decrease was only statistically significant
for GW-treated mice (−30%) (Figure 3M).
Effect of GW and AICAR on satellite cell activation and
muscle regeneration and degeneration
We found that the number of dMHC-positive fibers was
significantly decreased in the drug-treated groups
Figure 3 Effect of GW and AICAR on mitochondrial activity. Fluorescent-activated cell scanning (FACS) of primary myoblasts isolated from
untreated and drug-treated mdx mice. Representative dot plot FACS overlay of mitochondrial mass with nonyl acridine orange (NAO) staining
(A and B) and staining for mitochondrial activity with 3, 3’-dihexyloxacarbocyanine iodide (DiOC6) in myoblasts derived from the muscles of
treated mice (C, D). Histograms show geometric mean fluorescence of NAO and DiOC6 in dystrophin-deficient myoblasts. Quantification of
mRNA expression of PGC-1 α (E), Cyt c (F) and PDK-4 (G) relative to GAPDH mRNA expression by RTqPCR in gastrocnemius with n = 2 for each
group. Quantification of NADH activity in histological sections of EDL (H) and soleus (I) muscles, with immunolabeling of the soleus muscle for
Type I (J) and type IIA (K) fibers. (L) EDL twitch force parameters, ratio of the maximal twitch force (Pt) to the time required to reach this
force (tpt), and (M) lactate dehydrogenase activity of TA muscle. All experiments involved vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8),
and GW&AICAR-treated (n = 6) mice. Data are means ± SE. * P < 0.05 vs. vehicle-treated control mice. **P < 0.01 vs. vehicle-treated control mice.
*** P < 0.001 vs. vehicle-treated control mice.
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muscle cells was markedly decreased in the GW- and
combination-treated groups (Figure 4C). Furthermore,
the number of EDL fibers without central nucleation
increased in the single-treated groups (Figure 4D). Im-
portantly, miRNA31a expression, known to be associated
with muscle regeneration/degeneration, was significantly
down-regulated in diaphragms of treated mice (GW,
-28%; AICAR, -63%; GW&AICAR, -67%) (Figure 4E).miRNA133 was also increased in the treated groups, but
the differences did not reach statistical significance (data
not shown). Expression of FoXO1, which controls muscle
wasting, was decreased in AICAR (−34%) and combin-
ation drug-treated mice (−36%)(Figure 4F). Serum CK
levels showed huge variations but no statistically signifi-
cant changes (data not shown). Finally, IgM immunos-
taining was significantly decreased in gastrocnemius
sections of treated muscle (GW, -48%; AICAR, -69%;
Figure 4 Effect of GW and AICAR on satellite cell activation, muscle regeneration, and degeneration. (A) Immunostaining of
gastrocnemius muscle for developmental myosin (MyoD) heavy chain. (B) Histogram representing the area of regenerating fibers in
gastrocnemius muscle. (C) Percentage of MyoD-positive cells isolated from muscles. (D) Fibers with no central nuclei. (E) MiRNA expression in
diaphragm muscle (n = 4 for each group). (F) Western blotting for FoXO1 in EDL muscle lysate. Vinculin was used as an internal control for
protein loading. The expression was normalized to that of vinculin and expressed as a percentage of the vehicle expression. (G) IgM-positive
immunolabeling of muscle section to identify degenerated fibers. Data are means ± SE from vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8),
and GW&AICAR-treated (n = 6) mice. * P < 0.05 vs. vehicle-treated control mice. **P < 0.01 vs. vehicle-treated control mice. *** P < 0.001
vs. vehicle-treated control mice.
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gested a strong reduction in muscle degeneration.
Effect of GW and AICAR on diaphragm fibrosis, utrophin
A expression, muscle cytokines, and inflammation
Utrophin expression in skeletal muscle was studied be-
cause some of these improvements may have been due to
utrophin expression [17]. The level of utrophin A was
significantly increased in the treated groups over that in
untreated mice (GW, +112.97%,; AICAR, +84.97%;
GW&AICAR, +94.19%) (Figure 5A). We also measured
fibrosis in the diaphragm which occurs early in the dis-
ease and serves as a useful marker for assessing diseaseprogression and response therapy. We found that the
red-positive area was significantly decreased in the
treated groups (GW501516, -25.6%; AICAR, -27.5%;
GW&AICAR, -27.2%) (Figure 5B). Evaluation of cytokine
expression in TA muscle lysate revealed that mdx mice
had significantly increased IL-6 and IL-10 levels. Drug
treatment did not significantly affect IL-6 expression
(Figure 5C), but IL-10 levels were significantly decreased
in GW&AICAR-treated mice (−45%) (Figure 5D), and
not in individual drug-treated mice. EDL muscle demon-
strated a statistically significant decrease in inflammatory
infiltrates in the GW group but not the other two groups
(Figure 5E).
Figure 5 Effect of GW and AICAR on diaphragm fibrosis, utrophin A expression, muscle cytokines, and inflammation. (A) Western
blotting for utrophin in EDL muscles from vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8), and GW&AICAR-treated (n = 6) mice. Vinculin was used as
an internal control for protein loading. The expression was normalized to that of vinculin and expressed as a percentage of the vehicle
expression. (B) Van Gilson staining of the diaphragms of mice treated with vehicle, GW501516, AICAR, or GW&AICAR. The percentage of fibrosis
was then calculated by measuring the area of the fibrosis and the area of the whole section from vehicle- (n = 8), GW- (n = 6), AICAR- (n = 8),
and GW&AICAR-treated (n = 6) mice. IL-6 (C) and IL-10 (D) analyses were performed by flow cytometry on EDL muscle lysate (n = 2), with 30,000
events per tube. WT muscle was used as a control for cytokine expression. (E) Inflammation was also analyzed by Histologic examination
after H&E staining (1 inflammation = a cluster of 10 nuclei). Data are means ± SE. * P < 0.05 vs. vehicle-treated control mice.
**P < 0.01 vs. vehicle-treated control mice.
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In this study, we have demonstrated that dystrophic
muscle displays mitochondrial dysfunction similar to
that in golden retriever muscular dystrophy [18]. Meta-
bolic impairment has previously been reported [19], and
dystrophin-deficient myoblasts have been described as
having a pronounced respiratory impairment [20]. This
deficiency is not the primary cause of muscle weakness
in dystrophin deficiency; however, it may play a signifi-
cant additional role that can be important for the time
course of the disease. Defects in fatty acid oxidation
leads to the accumulation of fatty acylCoA and diacylgly-
cerol, inducing insulin signaling disruption and causing
muscle atrophy [21]. Similarly, alterations in mitochon-
drial functions caused by mtDNA mutations are
involved in muscle loss during aging [22]. Mitochondrial
fission and remodeling also contribute to muscle atrophyin mice [23]. Conversely, oxidative capacity activation
decreases muscle wasting in most cases [10]. Recently,
PPARδ have been demonstrated to be involved in satel-
lite cells proliferation and muscle regeneration [24].
Moreover, PGC-1α overexpression inhibits muscle atro-
phy during fasting and denervation [3] and significantly
improves dystrophic muscle [25]. Grumati et al. have
demonstrated that correcting mitochondrial impairment
in collagen VI deficiency significantly improves muscle
function [26]. Therefore, strategies that target mitochon-
drial up-regulation may be beneficial to dystrophic
muscle.
In the present study, we have used two known
endurance-mimetic drugs, AICAR and GW501516, to
activate endurance exercise-induced signaling pathways.
AICAR is a mimetic of endurance training that activates
AMPK activity, an energy status sensor in the cell [27].
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raises the level of PGC-1α expression and increases
mitochondrial biogenesis in muscle [28], reducing
muscle fatigability and increasing muscle performance
[12]. GW501516 is a PPARβ/δ agonist, a transcription
factor that is co-activated by PGC-1α. Like AICAR, this
drug is known to increase the amount of mitochondria
and promote mitochondrial metabolism [29,30] and fatty
acid oxidation [31] in vivo and in vitro and has been
tested as a therapeutic for type II diabetes [29,31,32].
More interestingly, the increase in muscle performance
that is stimulated by PPARδ/β activity is independent of
exercise training in mice [33] and combination treat-
ments with these drugs have been shown to have syner-
gistic beneficial effects in vivo in WT mice [12].
Our study clearly demonstrates that endurance
mimetics improve muscle function and overall activity in
dystrophic mice. The stimulation of mitochondrial bio-
genesis by GW501516 and/or AICAR that we have
observed is consistent with previous studies [31,33-35].
Miura et al. reported the use of GW501516 to slow the
myogenic program and increase utrophin A expression
in 5 weeks old mdx mice. More recently, Ljubicic et al
have reported that AICAR supplementation accompan-
ied with bout of exercise also improve muscle function
in 5 weeks old MDX mice. In our study, we have further
shown a decrease in LDH activity in TA muscles and in-
crease in NADH activity, together with an increase in
type I/IIA fibers in soleus muscle, an increase of mRNA
expression of PGC-1α, cyt c and a trend for PDK-4 sug-
gesting that the phenotype of treated muscle shifts from
glycolytic to oxidative type. Recently, Selsby et al. found
that enhancing PGC-1α expression rescues dystrophic
muscle and that a switch from fast - to slow -twitch
muscle is involved [25]. Moreover, utrophin expression
increased, as in Miura et al., and could be part of the
process of improving muscle function. Evidence suggests
that utrophin is likely to compensate for the lack of dys-
trophin in DMD muscle [17,36] and to decrease muscle
pathology [37,38]. This suggests the possibility that the
increase of Utrophin A might partly restore the dys-
trophin associated glycoprotein and help to improve
muscle function. Slow-twitch fibers have been reported
to have higher utrophin expression than do fast-twitch
fibers. Therefore, the increase in utrophin expression
with treatment could be a result of the change in fiber
metabolism. The presence of fibers with no central nu-
clei and the increase in peripheral nuclei suggest that de-
generation/regeneration has been halted by this
therapeutic intervention. This evidence is further corro-
borated by the concomitant down-regulation of activated
satellite cells and dMHC-positive regenerated fibers and
a decrease in miRNA-31, which are involved in muscle
degeneration [39]. Stabilization of myofiber structure issuggested by a marked decrease in FoXO1 and IgM ex-
pression in fibers. Together, these results clearly indicate
that muscle degeneration is decreased in treated mice.
FoXO1 transcription is lower in high-oxidative mouse
soleus than in low-oxidative gastrocnemius, TA, and
quadriceps muscles [40]. In vivo, FoXO1 inhibits high
oxidative fiber-related gene expression and oxidative
metabolism-enhancing factor activity [41]. Skeletal mus-
cles of FoXO1-over-expressing mice had fewer type I
fibers, as well as smaller type I and type II fibers [41].
The phenotype of our treated mice became more oxida-
tive, consistent with this change. A decrease in muscle
degradation could explain the diminution in satellite cell
activation that we observed.
We also found a decrease in inflammation and fat tis-
sue in the treated mice. Increased IL-6 levels are
involved in metabolic and structural changes in muscle
and in muscle loss during cachexia [42]. However, IL-6
inhibition has significantly reversed skeletal muscle wast-
ing in rodents [42]. Our data suggest that also
GW501516 and AICAR improve muscle function
through inflammation down-regulation. Adipose tissue
plays a crucial endocrine role through the production of
adipokines. Aberrant intracellular signaling cascades that
regulate both inflammatory and immune processes are
known to contribute substantially to degeneration
[43,44]. Therefore, fat reduction is very interesting, since
it can reduce inflammation and have an impact on both
degeneration and regeneration. GW501516 has been
shown to be involved in inflammatory pathway regula-
tion [45]. However, further experiments are needed to
delineate the link between proinflammatory fat tissue
and muscle inflammation.Conclusions
In summary, this study demonstrates that the use of en-
durance mimetics in mdx mice induces an improvement
in the structural integrity and reduces the degeneration/
regeneration of mdx mouse muscle, probably through an
increase in oxidative metabolism in the fibers. Our study
and other recent work underline the high potential of
pharmacological activators of AMPK and PPARδ as part
of rational drug treatments for muscular dystrophies.Abbreviations
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deshydrogenase; mtDNA: mitochondrial Deoxyribonucleic acid;
NADH: Nicotinamide adenine dinucleotide; NAO: 10-nonyl acridine orange;
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receptor gamma coactivator 1-alpha; PPARδ: Peroxisome proliferator-
activated receptor delta.
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